New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Good momentum in commercial CDMO business
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Subscribe To Our Newsletter & Stay Updated
